Some tips on 76982-23-5

76982-23-5 5-Bromoquinoxaline 610437, aquinoxaline compound, is more and more widely used in various fields.

76982-23-5, 5-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

76982-23-5, 5-Bromoquinoxaline (300 mg, 1.44 mmol) and di-tert-butyl hydrazine-1,2-dicarboxylate (500 mg, 2.15 mmol) were dissolved in DMF (5 mL). CuI (27.5 mg, 0.14 mmol) and K3PO4 (609.3 mg, 2.87 mmol) were added and purged with N2, cyclohexane-1,3-diamine (32.8 mg, 0.29 mmol) was added and the reaction mixture was stirred at 110 C. for 16 h. The reaction mixture was filtered through a pad of diatomaceous earth and the pad was washed with EtOAc (20 mL*3). The filtrate was concentrated under reduced pressure to afford a crude produce as a brown oil. The crude product was purified by column chromatography over silica gel (petroleum ether/ethyl acetate=100:0 to petroleum ether/ethyl acetate=50:50), and the solvents were removed under reduced pressure to afford compound 66a as a brown oil (0.3 g, 58%). LCMS (ESI): m/z 383.0 [M+H]+.

76982-23-5 5-Bromoquinoxaline 610437, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; Janssen Biotech, Inc.; Lu, Tianbao; Allison, Brett Douglas; Barbay, Joseph Kent; Connolly, Peter J.; Cummings, Maxwell David; Diels, Gaston; Edwards, James Patrick; Kreutter, Kevin D.; Philippar, Ulrike; Shen, Fang; Thuring, Johannes Wilhelmus John Fitzgerald; Wu, Tongfei; (412 pag.)US2018/170909; (2018); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

Analyzing the synthesis route of 50998-17-9

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9

To a solution of 11e (70.0 mg, 296 mumol), 6-bromoquinoxaline (94.1 mg, 450 mumol), Bu4NOAc (181 mg, 600 mol) and Pd(OAc)2 (10.1 mg, 45.0 mol) in NMP (0.6 mL). The reaction mixture was stirred for 23 h at 100 oC and cooled to room temperature. The mixture was concentrated under reduced pressure. Diluted with water and extracted with EtOAc (3 ¡Á 5 mL). The EtOAc solution was washed with brine (5 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (1:1 hexane/EtOAc) to afford the compound 12d (15 mg, 14%) as a yellow solid. TLC: Rf 0.2 (1:1 hexane/EtOAc). mp: 208-210 oC. 1H-NMR (400 MHz, CDCl3) delta 8.89 (d, 1H, J = 1.6Hz), 8.85 (d, 1H, J = 1.6 Hz), 8.12 (d, 1H, J = 8.4 Hz), 8.07 (d, 1H, J = 1.6 Hz), 7.76 (dd, 1H, J = 8.4 Hz, J = 2.0 Hz), 7.73 (t, 1H, J = 7.6 Hz), 7.64 (d, 1H, J = 7.6 Hz), 7.59-7.57 (m, 2H), 7.30-7.27 (m, 3H), 7.12 (d, 1H, J = 7.6 Hz), 2.18 (s, 3H). 13C-NMR (100 MHz, CDCl3) delta 158.3, 149.1, 146.2, 145.9, 145.8, 143.0, 142.7, 139.1, 132.6, 132.4, 131.6, 131.0, 130.4, 129.5, 128.8, 128.4, 127.8, 123.7, 115.7, 23.8. HRMS (ESI) calcd. for C22H17N6 (M+H): 365.1509; found 365.1512.

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Article; Li, Fei; Park, Yunjeong; Hah, Jung-Mi; Ryu, Jae-Sang; Bioorganic and Medicinal Chemistry Letters; vol. 23; 4; (2013); p. 1083 – 1086;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

New learning discoveries about 887590-25-2

As the paragraph descriping shows that 887590-25-2 is playing an increasingly important role.

887590-25-2, tert-Butyl 3,4-dihydroquinoxaline-1(2H)-carboxylate is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

887590-25-2, 11.2: trans-4-(5-Hydroxyadamantan-2-ylcarbamoyl)-3,4-dihydro-2H-quinoxaline-1-carboxylic acid tert-butyl ester 0.4 g of 3,4-dihydro-2H-quinoxaline-1-carboxylic acid tert-butyl ester is placed in 8 ml of dichloromethane at 0 C. under nitrogen. 0.69 ml of triethylamine and 0.202 g of triphosgene are added. The mixture is stirred at ambient temperature for 3 h, then 1 ml of dimethylformamide and 0.285 g of trans 4-aminoadamantan-1-ol are added and stirring is maintained for 18 h. The reaction medium is washed with a saturated aqueous sodium hydrogencarbonate solution. The organic phase is dried over magnesium sulphate and concentrated to dryness. The crude product obtained is chromatographed on silica gel, elution being carried out with a gradient of a dichloromethane/methanol (99/1 to 95/5) mixture. 0.54 g of trans-4-(5-hydroxyadamantan-2-ylcarbamoyl)-3,4-dihydro-2H-quinoxaline-1-carboxylic acid tert-butyl ester is obtained. M+H+=428

As the paragraph descriping shows that 887590-25-2 is playing an increasingly important role.

Reference£º
Patent; SANOFI-AVENTIS; US2011/9391; (2011); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

Downstream synthetic route of 49679-45-0

49679-45-0 Ethyl 3-chloroquinoxaline-2-carboxylate 12283436, aquinoxaline compound, is more and more widely used in various fields.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.49679-45-0,Ethyl 3-chloroquinoxaline-2-carboxylate,as a common compound, the synthetic route is as follows.

A suspension of 3-chloroquinoxaline-2-carboxylate (86.0 g, 363 mmol), trimethylboroxine (22.8 g, 0.182 mmol), [1,1 ‘- bis(diphenylphosphino) ferrocene] dichloropalladium(II) (8.90 g, 11.0 mmol), and potassium carbonate (100 g, 727 mmol) in 1,4-dioxane (726 mL) was heated at 115 C for 4 h. And then trimethylboroxine (22.8 g, 0.182 mmol) was added again and heated at same temperature for 2 h. After being cooled to ambient temperature, the reaction mixture was diluted with ethyl acetate (700 mL) and filtrated through celite with ethyl acetate (1000 mL). The filtrate was combined and concentrated in vacuo. The residue was purified by silica gel column chromatography (silica gel 900 g, hexane: ethyl acetate = 9: 1 to 17:3) followed by recrystallization from cold hexane to give ethyl 3- methylquinoxaline-2-carboxylate. MS (APCI): m/z 217 (M+H)., 49679-45-0

49679-45-0 Ethyl 3-chloroquinoxaline-2-carboxylate 12283436, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; MITSUBISHI TANABE PHARMA CORPORATION; KAWANISHI, Eiji; HONGU, Mitsuya; TANAKA, Yoshihito; WO2011/105628; (2011); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

Downstream synthetic route of 50998-17-9

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,50998-17-9

EXAMPLE 622,5-Dimethyl-5-[3-(quinoxalin-6-yl)phenyl1tetrahydrofuran-2-ol6-Bromoquinoxaline (3.14 g, 15 mmol) was dissolved in DME/water (9:1, 500 niL), and 3-acetylphenylboronic acid (2.5 g, 15 mmol), cesium carbonate (9.75 g, 30 mmol) and Pd(PPh3 )4 (870 mg, 0.75 mmol) were added. The mixture was heated to 1100C for 18 h. After cooling, the mixture was partitioned between EtOAc and water (100 mL each), and the organic phase concentrated in vacuo. The residue was triturated with diethyl ether (50 mL) to give l-[3-(quinoxalin-6-yl)phenyl]ethanone (3.8 g, >95%). LCMS (ES+) 249.2 (M+H)+, RT 3.04 minutes. A sample of this material (500 mg, 2 mmol) was dissolved in THF (4 mL), and cooled to O0C. But-l-en-4-ylmagnesium bromide (0.5M in THF, 4 mL, 2 mmol) was added and the mixture allowed to warm to room temperature. After stirring for 2 h, water (2 mL) was added. The organic phase was passed though a silica plug and concentrated in vacuo. The residue was dissolved in DCM (3 mL). 7V-Bromosuccinimide (146 mg, 0.9 mmol) was added and the mixture stirred at room temperature for 18 h. The mixture was partitioned between DCM (5 mL) and saturated sodium hydrogencarbonate solution (5 mL). The organic phase was passed through a silica plug and the filtrate concentrated in vacuo. The residue was dissolved in MeOH (3 mL). Sodium methoxide (200 mg) was added and the mixture was stirred at 600C for 3 days. The mixture was neutralized to pH 7.0 with IM hydrochloric acid and then concentrated in vacuo. The residue was purified by preparative HPLC to isolate the title compound (5 mg, 2:1 mixture of cis:trans isomers). deltaH (CDCl3) 8.89 (d, IH), 8.86 (d, IH), 8.32 (m, IH), 8.20 (m, IH), 8.08 (m, IH), 7.84 (m, IH), 7.62 (m, IH), 7.50 (m, 2H), 2.10-2.58 (m, 4H), 2.11 (s, 3H), 1.56-1.72 (m, 4H). LCMS (ES+) 321.3 (M+H)+, RT 2.93 minutes.

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; UCB PHARMA S.A.; BUeRLI, Roland; HAUGHAN, Alan, Findlay; MACK, Stephen, Robert; PERRY, Benjamin, Garfield; RAPHY, Gilles; SAVILLE-STONES, Elizabeth, Anne; WO2010/52448; (2010); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

Brief introduction of 148231-12-3

The synthetic route of 148231-12-3 has been constantly updated, and we look forward to future research findings.

148231-12-3, 5,8-Dibromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

In 100ml three-necked flask, 5,8-dibromo quinoxaline 1.00g (3.47mmol), 4- (4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl) pyridine 3 .27g (15.97mmol), tetrakistriphenylphosphinepalladium 0.401g (0.347mmol), as a phase transfer catalyst, adding Aliquat336 (Aldrich) 0.150g (0.371mmol), after argon gas replacement, sequentially added degassed 1,4-dioxane 27ml and 1M- potassium carbonate aqueous solution 22ml with argon gas, after the reflux at 105 15 hours, the reaction solution after returning to room temperature, the chloroform and was added saturated brine . The solution was transferred to a separatory funnel, and the organic layer was washed with saturated brine, after dehydration by stirring at room temperature for 1 hour over magnesium sulfate as a drying agent to the organic layer, then palladium scavenger silica gel (Aldrich the Ltd.) was stirred for 1 hour at 2g was added at room temperature to remove residual palladium in the organic layer. After filtering off the drying agent and silica gel, and the solvent was evaporated under reduced pressure. The crude product was purified by silica gel column chromatography (toluene / acetone = 1/2) to obtain a desired product. The yield 0.78g, 79% yield., 148231-12-3

The synthetic route of 148231-12-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; RICOH COMPANY LIMITED; HIRANO, SHIGENOBU; OKADA, TAKASHI; SAGISAKA, TOSHIYA; SATO, TSUTOMU; (22 pag.)JP5811808; (2015); B2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

Downstream synthetic route of 50998-17-9

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

50998-17-9, INTERMEDIATE 13 -(Quinoxalin-6-yl)benzaldehydeA mixture of 6-bromoquinoxaline (210 mg, 1.01 mmol), 3-formylphenylboronic acid (301 mg, 2.01 mmol), 2M aqueous sodium carbonate solution (1.7 mL, 14.4 mmol) and Pd(PPh3)4 (35 mg, 0.03 mmol) in DME (3.5 mL) was heated to 1200C in a sealed tube, under microwave irradiation, for 20 minutes. After cooling, the organic phase was adsorbed onto silica and purified by column chromatography (SiO2, 10-100% EtOAc in heptane) to give the title compound (340 mg) as a beige solid. 6H (CDCl3) 10.15 (s, IH), 8.91 (d, IH), 8.89 (d, IH), 8.38 (d, IH), 8.26-8.31 (m, IH), 8.24 (d, IH), 8.10 (dd, IH), 8.02-8.07 (m, IH), 7.94-8.00 (dd, IH), 7.72 (t, IH). LCMS (ES+) 235 (M+H)+, RT 2.99 minutes.

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; UCB PHARMA S.A.; BUeRLI, Roland; HAUGHAN, Alan, Findlay; MACK, Stephen, Robert; PERRY, Benjamin, Garfield; RAPHY, Gilles; SAVILLE-STONES, Elizabeth, Anne; WO2010/52448; (2010); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

Simple exploration of 49679-45-0

49679-45-0, The synthetic route of 49679-45-0 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.49679-45-0,Ethyl 3-chloroquinoxaline-2-carboxylate,as a common compound, the synthetic route is as follows.

(1) To a solution of ethyl 3-chloroquinoxaline-2-carboxylate (2.00 g, 8.41 mmol) was added sodium methoxide (28% in methanol, 3.60 g, 18.7 mmol) at 0 C. After being stirred for 1 hour at room temperature, the reaction mixture was diluted with dichloromethane (200 mL). The solution was neutralized with ammonium chloride and filtrated through celite. The filtrate was combined and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=9:1 to 3:2), followed by trituration with hexane to give ethyl 3-methoxyquinoxaline-2-carboxylate as colorless powder (1.37 g, 74%). MS (APCI): m/z 219 (M+H).

49679-45-0, The synthetic route of 49679-45-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Kawanishi, Eiji; Matsumura, Takehiko; US2011/160206; (2011); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

Some tips on 50998-17-9

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9

After adding 6-bromoquinoxaline (3.8 g, 18.2 mmol), n-butyl vinyl ether (12.3 mL, 95.2 mmol), potassium carbonate (3.1 g, 22.8 mmol), 1,3-bis(diphenylphosphino)propane (504 mg, 1.3 mmol) and palladium(II) acetate (124 mg, 0.5 mmol) to N,N-dimethylformamide (47 mL) and water (6 mL), the result was stirred and refluxed for 6 hours. After terminating the reaction, the result was cooled to room temperature, 2 N hydrochloric acid was added thereto, and the result was stirred for 0.5 hours. Ethyl acetate was added thereto, the organic layer was washed with water and sodium bicarbonate, dried using anhydrous magnesium sulfate, and filtered. The filtrate was concentrated and purified using column chromatography to obtain a target compound (2.4 g). 1H NMR spectrum (300 MHz, DMSO-d6) delta 10.05(d, 1H), 9.73(t, 1H), 8.71(s, 1H), 7.97(d, 1H), 3.16(s, 3H).

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; Hanmi Pharmaceutical Co., Ltd.; LEE, Kyung Ik; JUNG, Young Hee; SONG, Ji Young; JUN, Seung Ah; (89 pag.)EP3480193; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

Simple exploration of 887590-25-2

887590-25-2 tert-Butyl 3,4-dihydroquinoxaline-1(2H)-carboxylate 16740533, aquinoxaline compound, is more and more widely used in various fields.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.887590-25-2,tert-Butyl 3,4-dihydroquinoxaline-1(2H)-carboxylate,as a common compound, the synthetic route is as follows.

887590-25-2, 12.2: 4-{4-[4-(Pyridin-4-yloxy)piperidin-1-yl]phenyl}-3,4-dihydro-2H-quinoxaline-1-carboxylic acid tert-butyl ester 1.2 g of 4-[1-(4-bromophenyl)piperidin-4-yloxy]pyridine are placed in 20 ml of anhydrous o-xylene. 0.844 g of 3,4-dihydro-2H-quinoxaline-1-carboxylic acid tert-butyl ester is added, then 0.519 g of sodium tert-butoxide is added, followed by 0.032 g of palladium acetate, and then addition is completed with 0.029 g of tri(tert-butyl)phosphine. The reaction mixture is heated at 150 C. for 6 h. Heating is subsequently halted, the mixture is brought back to ambient temperature and ethyl acetate is added. The mixture is washed twice with water and then twice with a saturated aqueous sodium chloride solution. The organic phase is dried over sodium sulphate and concentrated under reduced pressure. The crude product obtained is chromatographed on silica gel, elution being carried out with a gradient of a dichloromethane/methanol (99/1 to 97/3) mixture. 1.1 g of 4-{4-[4-(pyridin-4-yloxy)piperidin-1-yl]phenyl}-3,4-dihydro-2H-quinoxaline-1-carboxylic acid tert-butyl ester are obtained. M+H+=487

887590-25-2 tert-Butyl 3,4-dihydroquinoxaline-1(2H)-carboxylate 16740533, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; SANOFI-AVENTIS; US2011/9391; (2011); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider